FIELD: medicine.
SUBSTANCE: invention is related to a method for correcting cognitive impairment in patients during the period of convalescence of a coronavirus infection caused by the SARS-CoV-2 virus. The method for correcting cognitive impairment in patients during the period of convalescence of a coronavirus infection caused by the SARS-CoV-2 virus includes daily, for 30-90 days, oral administration of a therapeutic complex according to the following scheme: inosine 200 mg 3 times a day before meals; iron bisglycinate 25 mg once a day with meals; or inosine 200 mg 3 times a day before meals for 7 days, then 400 mg 3 times a day before meals until the end of the correction course, iron bisglycinate 25 mg 1 time per day with meals.
EFFECT: above method increases the clinical effectiveness of the correction of cognitive impairment after a coronavirus infection caused by the SARS-CoV-2 virus due to the pathogenetic regulating therapeutic effect on metabolic processes in the cells of the central nervous system.
2 cl, 5 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR INCREASING EFFECTIVENESS OF BASIC PSYCHOPHARMACOLOGICAL THERAPY OF MIXED ANXIETY AND DEPRESSIVE DISORDER | 2023 |
|
RU2817950C1 |
METHOD OF PREDICTING THE RISK OF DEATH FROM COVID-19 IN YOUNG PATIENTS | 2023 |
|
RU2803002C1 |
METHOD OF TREATING COVID-19 IN CHILDREN AT RISK OF SEVERE CLINICAL COURSE OF DISEASE | 2023 |
|
RU2815303C1 |
METHOD FOR COMPLEX THERAPY OF PEDIATRIC PATIENTS WITH VIRAL INFECTION USING PROBIOTIC FOOD PRODUCTS | 2021 |
|
RU2793833C1 |
METHOD FOR PREDICTING RISK OF DEATH AT HOSPITAL STAGE IN PATIENTS WITHOUT ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION WHO HAVE UNDERGONE NEW COVID-19 CORONAVIRUS INFECTION, TAKING INTO ACCOUNT THEIR IMMUNOLOGICAL STATUS | 2022 |
|
RU2781565C1 |
METHOD FOR EARLY DETECTION OF NEUROLOGICAL DISORDERS IN PATIENTS WITH COVID-19 | 2021 |
|
RU2779562C1 |
METHOD FOR TREATMENT OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN ASSOCIATED WITH SARS-CoV-2 | 2021 |
|
RU2780939C1 |
METHOD FOR PREDICTION OF LETHAL OUTCOME IN PATIENTS WITH CYTOKINE STORM ASSOCIATED WITH COVID-19 | 2022 |
|
RU2825710C2 |
METHOD FOR DETERMINING THE DEGREE OF RISK OF DEVELOPING CARDIOVASCULAR COMPLICATIONS IN COVID-19 | 2021 |
|
RU2768575C1 |
METHOD FOR DIAGNOSING MACROPHAGE ACTIVATION SYNDROME IN A NEW CORONAVIRUS INFECTION CAUSED BY THE SARS VIRUS - COV-2 | 2022 |
|
RU2778779C1 |
Authors
Dates
2023-08-08—Published
2022-12-28—Filed